March Madness for ETFs: 10 Funds Leading the Pack
Around the country, work places are growing increasingly restless knowing that March Madness begins Thursday and the betting pools are about to…
CNCR
Biotech ETFs Pop on Celgene, Juno Deal
Biotechnology sector-related ETFs surged Monday after Celgene (NasdaqGS: CELG) said it will acquire Juno Therapeutics (NasdaqGS: JUNO) to expand its cancer treatment…
Biotech ETFs Jump on Gilead, Kite Deal
The biotechnology segment rallied Monday with small-cap biotech names and related exchange traded funds leading the charge after Gilead Sciences (NasdaqGS: GILD)…
ETF Performance Report: October
The equities market and stock exchange traded funds ended October flat in muted action as a renewed FBI investigation into Democratic runner…
Pfizer Acquires Medivation, Renews Biotech M&A Bets
Pfizer (NYSE: PFE) announced a $14 billion deal to acquire cancer drug developer Medivation (NasdaqGS: MDVN), propelling the broader biotechnology exchange traded…
Health Care ETFs Can Still Strengthen on Increased M&A Activity
While the health industry has underperformed so far this year, health care stocks and sector-related exchange traded funds can gain momentum on…
Silver Lining for Biotechnology ETFs After Pfizer Calls off Allergan Deal
Pfizer (NasdaqGS: PFE) called off the deal with Allergan (NasdaqGS: AGN) on Wednesday, but there was a silver lining. Exchange traded funds…
The First Cancer Immunotherapy ETF
With the advancements in biotechnology generating some attractive investment opportunities, exchange traded fund investors may now focus on a group of companies…